Blue Faery: The Adrienne Wilson Liver Cancer Association

Home
United States
Houston, TX
Blue Faery: The Adrienne Wilson Liver Cancer Association

Blue Faery's mission is to prevent, treat and cure primary liver cancer, specifically Hepatocellular Carcinoma, through research, education and advocacy.

Blue Faery's mission is to prevent, treat and cure primary liver cancer, specifically Hepatocellular Carcinoma (HCC), through research, education and advocacy. RESEARCH

+To accelerate the acquisition and application of scientific understanding and to advance the diagnosis, treatment, prevention and cure of Hepatocellular Carcinoma.
+To increase the scientific understanding of the correlat

ion between hepatitis and Hepatocellular Carcinoma.
+To establish international alliances in a joint effort to find a cure for Hepatocellular Carcinoma.
+To make clinical trials and treatment options available to all patients diagnosed with Hepatocellular Carcinoma regardless of age, gender or ethnicity. EDUCATION

+To educate the public on the causes, symptoms, treatment options and prevention of Hepatocellular Carcinoma through lectures and literature developed by the organization, as well as through the use of Adrienne Wilson's name, likeness, personal story and medical case history.
+To educate the public on the correlation between hepatitis and Hepatocellular Carcinoma. ADVOCACY

+To increase influence with private and public organizations to achieve Blue Faery's goals.
+To increase awareness of Blue Faery among the general public in order to increase support for our mission and reach more people with the services we provide.
+To facilitate contact among patients with Hepatocellular Carcinoma, their families and healthcare providers for the purposes of support, exchange of knowledge and participation in clinical trials.

06/03/2026

𝗙𝗿𝗼𝗺 𝗢𝗯𝗲𝘀𝗶𝘁𝘆 𝗧𝗼 𝗛𝗲𝗽𝗮𝘁𝗶𝘁𝗶𝘀: 𝗪𝗵𝗮𝘁'𝘀 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗧𝗵𝗲 𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗜𝗻 𝗟𝗶𝘃𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝗺𝗼𝗻𝗴 𝗬𝗼𝘂𝗻𝗴 𝗔𝗱𝘂𝗹𝘁𝘀?
As a senior physician, I've witnessed countless struggles within the human body. Yet in the last year, I've noticed a stark new trend in my own practice: a palpable rise in liver cancer diagnoses in adults in their 30s and 40s. We used to think about this disease as belonging to older persons or those with years of excessive drinking. The patient's profile is now shifting, and we need to question why.

The explanation isn't one bad guy but a perfect storm of lifestyle issues of today and stealthy infections. The largest impetus behind this wave is an illness that rings innocuous but is not: Non-Alcoholic Fatty Liver Disease (NAFLD).

https://vist.ly/56h57

06/02/2026

A liver cancer diagnosis can change life in an instant – not only for the person facing it, but also for their loved ones. Bruce and Elena show how a diagnosis can reshape a relationship, and how love and determination can carry two people through even the hardest moments. 𝗛𝗲𝗮𝗿 𝗕𝗿𝘂𝗰𝗲 𝗮𝗻𝗱 𝗘𝗹𝗲𝗻𝗮'𝘀 𝗳𝘂𝗹𝗹 𝘀𝘁𝗼𝗿𝘆: https://vist.ly/56c7n
With Eisai US and

06/01/2026

𝗪𝗵𝗮𝘁 𝗗𝗼𝗲𝘀 𝗦𝘁𝗮𝗴𝗶𝗻𝗴 𝗠𝗲𝗮𝗻 𝗜𝗻 𝗟𝗶𝘃𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿?

Dr. Anjana Pillai, a professor of medicine and surgery, as well as the leader of multiple liver programs at UChicago Medicine, explains that staging plays a crucial role in determining the best treatment for patients with liver cancer in an interview with CURE.

Once imaging confirms a diagnosis, doctors assess the size, number and location of tumors, as well as whether they involve major blood vessels or bile ducts. Additional tests, such as a CT scan of the chest, help determine if the cancer has spread beyond the liver, most commonly to the lungs or bones. UChicago Medicine CureToday.online

https://vist.ly/56888

05/29/2026

𝗝𝗦𝗦 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗡𝗮𝘁𝘂𝗿𝗮𝗹 𝗖𝗼𝗺𝗽𝗼𝘂𝗻𝗱 𝗧𝗼 𝗧𝗮𝗿𝗴𝗲𝘁 𝗟𝗶𝘃𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿

Scientists at JSS Medical College, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, have uncovered the novel therapeutic potential of Sodium Butyrate against Hepatocellular Carcinoma (HCC), the most common form of liver cancer, by targeting the RNA Induced Silencing Complex (RISC) machinery and telomerase.

https://vist.ly/55x3n

05/28/2026

The Blue Faery team is officially ASCO-bound.

Some of our team is heading out today, and the rest will be joining us tomorrow. We are packing up, making our way to Chicago, and getting ready for an exciting few days of connection, conversation, and community.

This year feels especially meaningful because American Society of Clinical Oncology attendees will have the chance to meet some of the newest members of the Blue Faery team in person.

If you are attending ASCO, come find us at Booth 10013. Just look for the large blue wings. We would love to meet you, hear about your work, and share more about our mission to support people impacted by liver cancer.
https://vist.ly/55t73

05/27/2026

𝗔𝗱𝗱𝗲𝗻𝗯𝗿𝗼𝗼𝗸𝗲'𝘀 𝗕𝗲𝗴𝗶𝗻𝘀 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗟𝗶𝘃𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗙𝗼𝗿 𝗙𝗶𝗿𝘀𝘁 𝗡𝗛𝗦 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗜𝗻 𝗘𝘂𝗿𝗼𝗽𝗲

Cambridge University Hospitals NHS Foundation Trust (CUH) has become the first hospital in Europe to deliver histotripsy treatment to a patient outside of a clinical trial, following government fast-tracking, marking a major milestone in NHS cancer care. Cambridge University Hospitals NHS Foundation Trust

https://vist.ly/55nnt

05/26/2026

We're heading to !

Blue Faery will be at Booth 10013, and we would love to meet you. Stop by to learn more about our work supporting liver cancer patients, caregivers, clinicians, and researchers through education, advocacy, and community.

Come say hello; you'll know you've found us when you see the wings!
https://vist.ly/55iid

05/25/2026

𝗡𝘂𝗿𝘀𝗲-𝗟𝗲𝗱 𝗣𝗮𝗶𝗻 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗣𝗼𝘀𝘁-𝗧𝗔𝗖𝗘
The use of a nurse-led pain management model in patients undergoing transarterial chemoembolization (TACE) for liver cancer resulted in the improvement of several post-operative outcomes and fewer postoperative complications, according to a recent retrospective study.

Although other pain management models have been proposed, such as the enhanced recovery after surgery (ERA) protocol, these often require extensive infrastructure or specialized personnel, limiting applicability in interventional oncology departments, according to study researchers.

https://vist.ly/55eqa

05/22/2026

𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗢𝗳 𝗬-𝟵𝟬 𝗥𝗲𝘀𝗶𝗻 𝗠𝗶𝗰𝗿𝗼𝘀𝗽𝗵𝗲𝗿𝗲𝘀 𝗠𝗮𝗿𝗸𝘀 𝗔 𝗡𝗲𝘄 𝗖𝗵𝗮𝗽𝘁𝗲𝗿 𝗙𝗼𝗿 𝗥𝗮𝗱𝗶𝗼𝗲𝗺𝗯𝗼𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗜𝗻 𝗨𝗻𝗿𝗲𝘀𝗲𝗰𝘁𝗮𝗯𝗹𝗲 𝗛𝗖𝗖

SIR-Spheres Y-90 resin microspheres have been approved by the FDA for the treatment of patients with unresectable hepatocellular carcinoma (HCC), offering a new option for those with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status, according to Armeen Mahvash, MD.

The approval was supported by findings from the prospective, multicenter, open-label DOORwaY90 study (NCT04736121), which evaluated Y-90 as first-line therapy for patients with unresectable HCC.

https://vist.ly/557c2

05/20/2026

𝗪𝗵𝘆 𝗙𝗲𝗲𝗹𝗶𝗻𝗴 "𝗙𝗶𝗻𝗲" 𝗖𝗮𝗻 𝗕𝗲 𝗥𝗶𝘀𝗸𝘆 𝗜𝗻 𝗟𝗶𝘃𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝘀𝗲𝘀

Liver cancer may arise due to long-term issues such as viral hepatitis, fatty liver or heavy alcohol use, but it can often be prevented.

Surprisingly, those diagnosed with liver cancer always say, “they feel fine”. That’s because the liver is resilient; it can keep working yet compensate for damage, even when a large part is compromised. It’s difficult to accept when you feel healthy. This underlines why liver cancer often remains silent for a long time, especially among those with liver conditions or fatty liver disease. That is why regular scans and blood tests in such vulnerable groups make a significant difference.

https://vist.ly/54vv7

Address

Houston, TX
77477-1292

Website

https://loveyourliver.us/, https://www.bluefaery.org/, https://youandlivercancer.com/

Alerts

Be the first to know and let us send you an email when Blue Faery: The Adrienne Wilson Liver Cancer Association posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Blue Faery: The Adrienne Wilson Liver Cancer Association:

Featured

Psych Dimensions
Clinica San Jacinto Shotwell
723 Shotwell Street Suite B
Plaza Ob/Gyn Associates
1801 Binz Street, Suite 500